Now Accepting Submissions for Novel hMSC Applications in Europe and North America

Application Deadline:May 31, 2022

Award Total: Up to $10,000 in applicable RoosterBio® products to be used over a 12 month period

Human mesenchymal stromal cells (hMSCs) are a critical raw material for a growing number of emerging regenerative medicine (RM) applications including cell and gene therapies, engineered tissues, combination products/medical devices, and exosome / extracellular vesicle (EV) based therapies.

Submissions are encouraged from all areas of hMSC / exosome research, including but not limited to:

  • hMSC / exosome pre-clinical therapeutic discovery
  • hMSC-based genetic engineering methods and applications
  • Exosome / Extracellular vesicle potency assay development
  • Autologous hMSC manufacturing 
  • hMSC applications in longevity, oncology, or fertility
  • Novel Applications in hMSC bioprocessing

Applicants must be 18 years of age or older and be located within the United States / Canada / Europe and affiliated with an R&D lab at a University, Hospital, or Institutional setting with access to lab space for receiving products, properly storing, and executing proposed work. Awardees acknowledge/agree to RoosterBio’s standard Terms and Conditions along with additional terms outlined below.

RoosterBio is helping to advance these technologies through innovative products and processes, which are the foundation for standardized, highly-qualified hMSC bioprocess systems. These systems enable rapid adoption of hMSCs into a therapeutic program, easy scale-up and scale-out to produce clinically relevant cell numbers, and to ultimately streamline the path from R&D to Product Development to cGMP Manufacturing & Clinical Trials. Our vision is to accelerate hMSC and exosome-based therapy development to fuel the rapid commercialization of scalable regenerative cures.